Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania

Abstract:
DermAvance Pharmaceuticals, a privately held pharmaceutical company specializing in advanced technology applications for skin health and cosmetic dermatology, today announced it had received an investment from Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP). These funds are part of a Series B financing that will be used to complete the acquisition and commercialization of DA-007, a patent protected combination, second generation dermal filler.

DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania

BERYWN, PA | Posted on May 1st, 2008

Dermal fillers are used to reverse changes associated with aging and can reduce or eliminate wrinkles, raise scar depressions, enhance lips and replace soft-tissue volume loss, thus returning the dermis to its original youthful state. Current marketed fillers include market-leader Restylane, sold by Medicis Pharmaceutical, and Radiesse sold by Bioform.

"We were very pleased to be selected for an investment by Ben Franklin Technology Partners as a part of our Series B financing," says Keith Greathouse, DermAvance President and CEO. Partnering with Ben Franklin validates our technology and represents a significant step in our on-going financing plan for the company. We continue to speak with additional investors to augment this initial investment and expect to complete the Series B financing during the third quarter. The proceeds from the Series B financing will be used to in part to also prepare and file the registration package for U.S marketing approval and to plan for the commercial launch of DA-007.

Mr. Greathouse further stated that physicians and patients desire dermal fillers like DA-007 that are safe, non-animal derived, long-lasting, easy to administer, and cost effective. The facial regeneration market is emerging as a powerful force with the baby boomers coming of age, and the US dermal filler market is projected to reach $1 billion by 2012.

####

About DermAvance Pharmaceuticals
DermAvance Pharmaceuticals, Inc. is a privately held dermatology pharmaceutical company focused on commercializing unique, and innovative anti- aging products to enhance the health and appearance of skin. The company was founded to meet the rapidly growing demand for facial skin rejuvenation products. DermAvance already has launched four product lines in this explosive anti-aging category including: Hyalogy (nano hyaluronic acid), Vivelif(R) (acetyl hexapeptide-3), Arnika Forte to reduce bruising, and SOYA. DermAvance markets and sells products directly to dermatologists and aesthetic physicians for in-office dispensing.

About Ben Franklin Technology Partners of Southeastern Pennsylvania

Celebrating our 25th anniversary, BFTP/SEP is the region's catalyst for Stimulating Entrepreneurial Potential. Ben Franklin invests in innovative enterprises and creates commercialization pathways that generate wealth through science and technology. Part of a statewide network in Pennsylvania, BFTP/SEP provides entrepreneurs and established businesses with the Capital, Knowledge and Networks to compete in the global marketplace. BFTP/SEP has provided more than $130 million to grow more than 1,600 regional enterprises. BFTP/SEP is a founding partner of The Nanotechnology Institute(TM) (NTI), the Mid-Atlantic Nanotechnology Alliance (MANA(R)), Emerald Stage2 Venture Fund and the Minority Angel Investor Network. BFTP/SEP is part of the Commonwealth of Pennsylvania's Ben Franklin Technology Partnership. www.sep.benfranklin.org

For more information, please click here

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Sirrus's Issued Patent Portfolio Continues To Accelerate July 18th, 2018

FEFU scientists reported on toxicity of carbon and silicon nanotubes and carbon nanofibers: Nanoparticles with a wide range of applying, including medicine, damage cells of microalgae Heterosigma akashivo badly. July 18th, 2018

In borophene, boundaries are no barrier: Rice U., Northwestern researchers make and test atom-thick boron's unique domains July 17th, 2018

Tuning into quantum: Scientists unlock signal frequency control of precision atom qubits July 16th, 2018

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. to Provide Live Remote Access to Its Annual Meeting of Shareholders on June 12, 2018 June 12th, 2018

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Nanowire LED Innovator Aledia Announces 30 ($36M) Million Series-C Financing: Intel Capital Joins Existing Investors to Commercialize Certain Nanowire-LED Technologies for Mobile Displays January 29th, 2018

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

Nanomedicine

Nano-kirigami: 'Paper-cut' provides model for 3D intelligent nanofabrication July 13th, 2018

UMBC researchers develop nanoparticles to reduce internal bleeding caused by blast trauma July 13th, 2018

Researchers identify cost-cutting option in treating nail fungus with nanotechnology: GW researcher Adam Friedman, M.D., studied the potential use of nitric oxide-releasing nanoparticles to improve onychomycosis treatment July 11th, 2018

New sensor technology enables super-sensitive live monitoring of human biomolecules July 3rd, 2018

Announcements

Sirrus's Issued Patent Portfolio Continues To Accelerate July 18th, 2018

FEFU scientists reported on toxicity of carbon and silicon nanotubes and carbon nanofibers: Nanoparticles with a wide range of applying, including medicine, damage cells of microalgae Heterosigma akashivo badly. July 18th, 2018

In borophene, boundaries are no barrier: Rice U., Northwestern researchers make and test atom-thick boron's unique domains July 17th, 2018

Tuning into quantum: Scientists unlock signal frequency control of precision atom qubits July 16th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project